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PP-099 Effect of lamivudine and telbivudine on
biochemistry, virology and hepatohistology in
hepatitis B antiviral treatment
Q.L. Jin1 *, C. Wang1, H.Q. Yan1. 1Hepatobiliary and
pancreatic department First Hospital of Jilin University,
China
Purpose: To study the anti-HBV effect of lamivudine and
telbivudine on biochemistry, virology and hepatohistology.
Method: Patients are randomized into 2 groups, oral
lamivudine and oral telbivudine, for 2 years of observation
during which AST, ALT, HBV quantiﬁcation and changes in
hepatohistology before treatment and at week 52 were
examined periodically.
Results: After treatment of lamivudine and telbivudine, AST
and ALT returned to normal levels; HBVDNA negative rates
at week 24, week 52 and week 104 for the two drugs were
high, HBVDNA levels decreased signiﬁcantly at week 24,
and 52 for telbivudine drug group. HBeAg negative rates
(p = 0.032) and 52 week therapeutic response (p = 0.0155)
were signiﬁcantly higher for telbivudine. Viral breakthrough
rate at 52 week is low in telbivudine group. And the liver
biopsy showed inﬂammatory change (G) and ﬁbrosis (S)
both improved in two group (P< 0.05), but improvement of
inﬂammatory change (G) is more signiﬁcantly in telbivudine
group (P< 0.05).
Conclusion: Lamivudine and telbivudine exhibit good anti-
viral function yet telbivudine is superior to lamivudine in the
inhibition of HBVDNA replication, drug resistance rate, the
rebound of viral replication rate and also the improvement
of liver tissues.
PP-100 Prevalence of infection with delta virus in
patients positive for hepatitis B surface
antigen
S. Zaki1 *, M. Abou Khatwa1, H. Mikhail1. 1Microbiology,
Faculty of Medicine, Alexandria, Egypt
Background: During the past decade delta hepatitis virus
has captured the attention as it causes a major health
problem. Delta infection can occur in the presence of acute
or chronic HBV infection. Delta superinfection can transform
asymptomatic or mild chronic hepatitis B infection to
severe progressive chronic active hepatitis and cirrhosis
and accelerate the course of chronic active hepatitis B.
Aim: Detect the prevalence of infection with delta virus
in selected groups of patients recognised to be HbsAg
positive.
Subjects: The study was carried out on one hundred
serum samples collected from patients of different disease
categories:
1. 30 patients with Schistosomal hepatic ﬁbrosis.
2. 22 patients on maintenance haemodialysis.
3. 20 patients with acute hepatitis.
4. 14 cases with hepatocellular carcinoma.
5. 8 intravenous drug abusers.
6. 6 chronic asymptomatic hepatitis B surface antigen
carriers.
Methods: Previously mentioned groups were tested for the
presence of total antibody to hepatitis delta antigen using
ELISA. Anti-delta positive samples were tested for anti-
hepatitis B core antibodies of the IgM class to differentiate
between superinfection and coinfection.
Results: Twenty anti-delta positive samples were detected
(20%). The highest frequency of anti-HDV positivity was
found among Schistosomal hepatic ﬁbrosis patients (46.7%)
followed by drug abusers (25%), hepatocellular carcinoma
group (14.3%), and patients on maintenance haemodialysis
(9.09%). Non of the acute hepatitis B patients or chronic
asymptomatic HBsAg carriers showed Delta antibodies. Anti-
hepatitis B Core antibodies of the IgM class were absent in
all the twenty samples positive for anti-delta indicating
superinfection with HDV.
Conclusion: Hepatic Schistosomiasis enhances HDV
infection.
PP-101 Adiponectin and its receptors in patients with
chronic hepatitis B
J.Q. Zhang1 *. 1Beijing Ditan Hospital, Institute of
Infectious Diseases, Capital Medical University, China
Background: Adiponectin, one of the pro-inﬂammatory and
anti-inﬂammatory mediators, is released by the adipose
tissue, which has been shown to have the properties of anti-
obesity, anti-diabetic in patients with non-alcoholic fatty
liver diseases. It can initiate a broad rang of metabolic
and immunological effects. The animal and human data
also suggest that adiponectin may be beneﬁcial for liver
functions.
In this study, we examined the expression levels of
adiponectin and its receptors (adipoR2) in liver biopsies
of patients with chronic hepatitis B (CHB), which with
or without steatosis were investigated to assess the
relationship between adiponectin, its receptors and hepatic
steatosis, ﬁbrosis and inﬂammation.
Methods: Live biopsies from 89 patients with untreated
chronic hepatitis B (CHB) (30 steatosis VS 59 without
steatosis) were analyzed. The liver biopsies were
subjected to routine histological examination and stained
immunohistochemically for adiponectin and receptor2
(adipoR2).
Results: The two groups were comparable with respect
to demographic, biochemical, metabolic, histological and
viral characteristics. BMI, g-GT, FPG, Insulin and insulin
sensitivity estimated by the HOMA index were signiﬁcantly
higher in patients with steatosis. In patients with chronic
HBV, the insulin sensitizing adipokine adiponectin and its
receptor AdipoR2 was associated with steatosis. Adiponectin
maybe correlated with inﬂammation. But adiponectin and
its receptors were not associated with viral factors of HBV.
Our results suggest that the role of adiponectin might be
impaired in chronic hepatitis B with steatosis.
Conclusion: Reduced hepatic expression of adiponectin
and adipoR2 might be of pathophysiological relevance in
CHB patients with steatosis. These ﬁndings indicated that
reduced liver adiponectin expression may play an important
role in the pathogenesis and progression of CHB patients
with steatosis. However, which were not associated with
viral factors of HBV.
PP-102 Maternal HBsAg carrier and pregnancy
outcome
A. Aghamohammady1 *. 1Islamic Azad University, Sari
Branch, Iran
Aim: To assess the impact of maternal HBsAg carrier status
on pregnancy outcomes.
Method: One hundred ﬁfty carriers of hepatitis B surface
antigen (HBsAg) with singleton pregnancy, were compared
with two hundred controls matched for age and parity.
Results: Women with HBsAg carriers had higher incidences
of preterm labour (21.2% vs. 13.9%, P = 0.030), gestational
diabetes (23.2% vs. 11.6%, P = 0.001) and Apgar scores lower
7 in their infants at the 1st (12.5% vs. 1.6%, P < 0.001) and
5th minute (16.8% vs. 9%, P = 0.009).
Conclusions: HBsAg carriers have increased risk of
gestational diabetes mellitus, preterm labour and low apgar
scores.. The role of chronic HBV infection in pregnancy
complications is not clear and needs more investigation.
